Impaired interienkin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy

Authors
Azuma, H Oshima, M Ito, K Okuno, A Kawabata, I Banba, K Murahashi, H Sekine, T Kato, Y Ikebuchi, K Ikeda, H
Citation
H. Azuma et al., Impaired interienkin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy, EUR J PED, 159(8), 2000, pp. 633-634
Citations number
4
Categorie Soggetti
Pediatrics,"Medical Research General Topics
Journal title
EUROPEAN JOURNAL OF PEDIATRICS
ISSN journal
03406199 → ACNP
Volume
159
Issue
8
Year of publication
2000
Pages
633 - 634
Database
ISI
SICI code
0340-6199(200008)159:8<633:IIPITF>2.0.ZU;2-D
Abstract
Interleukin-2 production may be one of the underlying causes of Wiskott-Ald rich syndrome immunodeficiency and recombinant interleukin-2 administration (or an infusion of T-cells expanded by CD3 stimulation and rIL-2) is able, to some extent, to restore defective T-cell function.